EMMUNE INC — Department of Health and Human Services SBIR Phase I: NIAID

Description

DESCRIPTION provided by applicant We have engineered a synthetic antibody that neutralizes of HIV strains This antibody is built from the parts of CD and CCR that are recognized by HIV and is named andquot eCD Ig andquot The goal of our research program is now to maximize its efficacy A fundamental question for our effort and for the field as a whole is Which isotype of IgG has the properties that are most important for suppressing viral replication To answer this question we will eliminate problematic features of IgG and IgG that have historically presented a barrier to their use as therapeutics in humans and we will compare the ability of rhesus IgG IgG and IgG forms of eCD Ig to suppress SIV replication in macaques The isotype of eCD Ig that most completely suppresses viral replication will be advanced to human clinical trials PUBLIC HEALTH RELEVANCE The HIV pandemic continues to be a catastrophe for global health We are developing approaches based on a synthetic antibody named andquot eCD Ig andquot for treating and preventing HIV infection The proposed project will resolve a fundamental scientific question about how to most effectively treat or prevent HIV infection and indicate which is the best embodiment of eCD Ig to advance to human clinical trials